This raises theoretical concerns about oral contraceptive absorption
By promoting insulin release and inhibiting glucagon secretion, GLP-1 agonists effectively lower blood sugar levels, providing a valuable therapeutic option for individuals with type 2 diabetes
For patients focused on stronger weight loss, standard-dose semaglutide or tirzepatide may be the better starting point
Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
The biological reason is straightforward sublingual and buccal absorption of large peptide molecules like semaglutide is variable and generally lower than injection bioavailability
However, many insurance companies are starting to push back to manage their expenses
